ImmunoVaccine Inc. (TSE:IMV) insider Pierre Labbé purchased 20,800 shares of the stock in a transaction on Monday, February 12th. The shares were purchased at an average price of C$1.89 per share, for a total transaction of C$39,312.00.
ImmunoVaccine Inc. (IMV) remained flat at $C$1.89 during midday trading on Tuesday. 55,867 shares of the stock were exchanged, compared to its average volume of 143,038. ImmunoVaccine Inc. has a 1 year low of C$1.00 and a 1 year high of C$2.55. The firm has a market cap of $246.44, a PE ratio of -21.22 and a beta of 0.47.
Immunovaccine Inc, a clinical stage biopharmaceutical company, develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.
Receive News & Ratings for ImmunoVaccine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoVaccine and related companies with MarketBeat.com's FREE daily email newsletter.